British Journal of Cancer - Table of Contents alert Volume 116 Issue 5

If you are unable to see the message below, click here to view.

Advertisement Breast Cancer Now Catalyst Programme Grants  Apply now  We are inviting Expressions of Interest from researchers who are interested in using Pfizer drugs for preclinical or clinical breast cancer research from teams based at a single site or multiple sites in the UK and Europe. To apply please visit our website. TABLE OF CONTENTS Volume 116, Issue 5 (553-696) Published online 28 February 2017 In this issue Review Clinical Studies Translational Therapeutics Molecular Diagnostics Genetics & Genomics Epidemiology Also new today Advance online publication Digital Edition Follow us on Twitter Sign up for e-alerts Recommend to your library Web feed Subscribe Review Top Tissue-based next generation sequencing: application in a universal healthcare system Seán O Hynes, Brendan Pang, Jacqueline A James, Perry Maxwell and Manuel Salto-Tellez Br J Cancer 2017 116: 553-560; advance online publication, January 19, 2017; 10.1038/bjc.2016.452 Abstract | Full Text Clinical Studies Top Efficacy of fluoropyrimidine-based chemotherapy in patients with advanced biliary tract cancer after failure of gemcitabine plus cisplatin: retrospective analysis of 321 patients Bum Jun Kim, Changhoon Yoo, Kyu-pyo Kim, Jaewon Hyung, Seong Joon Park, Baek-Yeol Ryoo and Heung-Moon Chang Br J Cancer 2017 116: 561-567; advance online publication, January 12, 2017; 10.1038/bjc.2016.446 Abstract | Full Text A phase III randomised controlled trial of erlotinib vs gefitinib in advanced non-small cell lung cancer with EGFR mutations J J Yang, Q Zhou, H H Yan, X C Zhang, H J Chen, H Y Tu, Z Wang, C R Xu, J Su, B C Wang, B Y Jiang, X Y Bai, W Z Zhong, X N Yang and Y L Wu Br J Cancer 2017 116: 568-574; advance online publication, January 19, 2017; 10.1038/bjc.2016.456 Abstract | Full Text A phase 1 dose-escalation and expansion study of binimetinib (MEK162), a potent and selective oral MEK1/2 inhibitor Johanna C Bendell, Milind Javle, Tanios S Bekaii-Saab, Richard S Finn, Zev A Wainberg, Daniel A Laheru, Colin D Weekes, Benjamin R Tan, Gazala N Khan, Mark M Zalupski, Jeffrey R Infante, Suzanne Jones, Kyriakos P Papadopoulos, Anthony W Tolcher, Renae E Chavira, Janna L Christy-Bittel, Emma Barrett and Amita Patnaik Br J Cancer 2017 116: 575-583; advance online publication, February 2, 2017; 10.1038/bjc.2017.10 Abstract | Full Text Comparison of two protocols for the management of asymptomatic postmenopausal women with adnexal tumours – a randomised controlled trial of RMI/RCOG vs Simple Rules Natalie Nunes, Gareth Ambler, Xulin Foo, Joel Naftalin, Grigoris Derdelis, Martin Widschwendter and Davor Jurkovic Br J Cancer 2017 116: 584-591; advance online publication, February 2, 2017; 10.1038/bjc.2017.17 Abstract | Full Text Translational Therapeutics Top Aurora B expression modulates paclitaxel response in non-small cell lung cancer Ahmed SK Al-Khafaji, Michael PA Davies, Janet M Risk, Michael W Marcus, Maria Koffa, John R Gosney, Richard J Shaw, John K Field and Triantafillos Liloglou Br J Cancer 2017 116: 592-599; advance online publication, January 17, 2017; 10.1038/bjc.2016.453 Abstract | Full Text A combination of low-dose bevacizumab and imatinib enhances vascular normalisation without inducing extracellular matrix deposition L M Schiffmann, M Brunold, M Liwschitz, V Goede, S Loges, M Wroblewski, A Quaas, H Alakus, D Stippel, C J Bruns, M Hallek, H Kashkar, U T Hacker and O Coutelle Br J Cancer 2017 116: 600-608; advance online publication, January 31, 2017; 10.1038/bjc.2017.13 Abstract | Full Text Exosomes confer chemoresistance to pancreatic cancer cells by promoting ROS detoxification and miR-155-mediated suppression of key gemcitabine-metabolising enzyme, DCK Girijesh Kumar Patel, Mohammad Aslam Khan, Arun Bhardwaj, Sanjeev K Srivastava, Haseeb Zubair, Mary C Patton, Seema Singh, Moh'd Khushman and Ajay P Singh Br J Cancer 2017 116: 609-619; advance online publication, February 2, 2017; 10.1038/bjc.2017.18 Abstract | Full Text Neratinib resistance and cross-resistance to other HER2-targeted drugs due to increased activity of metabolism enzyme cytochrome P4503A4 Susan Breslin, Michelle C Lowry and Lorraine O'Driscoll Br J Cancer 2017 116: 620-625; advance online publication, February 2, 2017; 10.1038/bjc.2016.445 Abstract | Full Text Molecular Diagnostics Top Circular RNA 0000096 affects cell growth and migration in gastric cancer Peifei Li, Huilin Chen, Shengcan Chen, Xiaoyan Mo, Tianwen Li, Bingxiu Xiao, Rui Yu and Junming Guo Br J Cancer 2017 116: 626-633; advance online publication, January 12, 2017; 10.1038/bjc.2016.451 Abstract | Full Text MicroRNA promoter methylation: a new tool for accurate detection of urothelial carcinoma Nuno André Padrão, Sara Monteiro-Reis, Jorge Torres-Ferreira, Luís Antunes, Luís Leça, Diana Montezuma, João Ramalho-Carvalho, Paula C Dias, Paula Monteiro, Jorge Oliveira, Rui Henrique and Carmen Jerónimo Br J Cancer 2017 116: 634-639; advance online publication, January 12, 2017; 10.1038/bjc.2016.454 Abstract | Full Text Tenascin-C and fibronectin expression divide early stage tongue cancer into low- and high-risk groups Elias Sundquist, Joonas H Kauppila, Johanna Veijola, Rayan Mroueh, Petri Lehenkari, Saara Laitinen, Juha Risteli, Ylermi Soini, Veli-Matti Kosma, Iris Sawazaki-Calone, Carolina Carneiro Soares Macedo, Risto Bloigu, Ricardo D Coletta and Tuula Salo Br J Cancer 2017 116: 640-648; advance online publication, January 17, 2017; 10.1038/bjc.2016.455 Abstract | Full Text The predictive and prognostic value of tumour necrosis in muscle invasive bladder cancer patients receiving radiotherapy with or without chemotherapy in the BC2001 trial (CRUK/01/004) Ananya Choudhury, Catharine M West, Nuria Porta, Emma Hall, Helen Denley, Carey Hendron, Rebecca Lewis, Syed A Hussain, Robert Huddart and Nicholas James on behalf of the BC2001 investigators Br J Cancer 2017 116: 649-657; advance online publication, January 26, 2017; 10.1038/bjc.2017.2 Abstract | Full Text Genetics & Genomics Top Epigenomic landscape of 5-hydroxymethylcytosine reveals its transcriptional regulation of lncRNAs in colorectal cancer Hanyang Hu, Maoguo Shu, Lin He, Xueyuan Yu, Xiangyu Liu, Yalin Lu, Yinghong Chen, Xiaoping Miao and Xiaohua Chen Br J Cancer 2017 116: 658-668; advance online publication, January 31, 2017; 10.1038/bjc.2016.457 Abstract | Full Text The spectrum of EWSR1-rearranged neoplasms at a tertiary sarcoma centre; assessing 772 tumour specimens and the value of current ancillary molecular diagnostic modalities Jonathan Noujaim, Robin L Jones, John Swansbury, David Gonzalez, Charlotte Benson, Ian Judson, Cyril Fisher and Khin Thway Br J Cancer 2017 116: 669-678; advance online publication, January 31, 2017; 10.1038/bjc.2017.4 Abstract | Full Text Epidemiology Top Composite protective lifestyle factors and risk of developing gastric adenocarcinoma: the Singapore Chinese Health Study Zhensheng Wang, Woon-Puay Koh, Aizhen Jin, Renwei Wang and Jian-Min Yuan Br J Cancer 2017 116: 679-687; advance online publication, January 26, 2017; 10.1038/bjc.2017.7 Abstract | Full Text Circulating copper and zinc levels and risk of hepatobiliary cancers in Europeans Magdalena Stepien, David J Hughes, Sandra Hybsier, Christina Bamia, Anne Tjønneland, Kim Overvad, Aurélie Affret, Mathilde His, Marie-Christine Boutron-Ruault, Verena Katzke, Tilman Kühn, Krasimira Aleksandrova, Antonia Trichopoulou, Pagona Lagiou, Phlippos Orfanos, Domenico Palli, Sabina Sieri, Rosario Tumino, Fulvio Ricceri, Salvatore Panico, H B(as) Bueno-de-Mesquita, Petra H Peeters, Elisabete Weiderpass, Cristina Lasheras, Catalina Bonet Bonet, Elena Molina-Portillo, Miren Dorronsoro, José María Huerta, Aurelio Barricarte, Bodil Ohlsson, Klas Sjöberg, Mårten Werner, Dmitry Shungin, Nick Wareham, Kay-Tee Khaw, Ruth C Travis, Heinz Freisling, Amanda J Cross, Lutz Schomburg and Mazda Jenab Br J Cancer 2017 116: 688-696; advance online publication, February 2, 2017; 10.1038/bjc.2017.1 Abstract | Full Text Please note that you need to be a subscriber or site-licence holder to enjoy full-text access to British Journal of Cancer. In order to do so, please purchase a subscription. You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/nams/svc/myaccount (You will need to log in to be recognised as a nature.com registrant). For further technical assistance, please contact our registration department. For print subscription enquiries, please contact our subscription department. For other enquiries, please contact our customer feedback department. Nature Publishing Group |One New York Plaza, Suite 4500 | New York | NY 10004-1562 | USA Nature Publishing Group's worldwide offices: London - Paris - Munich - New Delhi - Tokyo - Melbourne San Diego - San Francisco - Washington - New York - Boston Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at The Campus, 4 Crinan Street, London, N1 9XW. © 2017 Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved.